Equity Research Medical Instruments & Supplies

Should You Buy AngioDynamics, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 3/13 models active

According to the CirclFi Deep Alpha Valuation Engine, AngioDynamics, Inc. (ANGO) carries a solid Quality of Company rating of 6.7/10. Trading at $15.78, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 0 of 3 CirclFi valuation models project upside for AngioDynamics, Inc. (ANGO) at $15.78 — the model consensus leans bearish, with a Quality Score of 6.7/10 and Value-Trap risk of 26/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 3 of 3 models suggest overvaluation — majority bearish
  • Quality Score: 6.7/10 — Moderate — mixed signals
  • Value Trap Risk: 26/100 — Low — manageable risk
  • Fair Value Range: $0.80 – $10.09 (1154% spread)

Bullish Models

0 / 3

Bearish Models

3 / 3

Quality Score

6.7 /10

Moderate — mixed signals

Value Trap Risk

26 /100
Low

Low — manageable risk

Model Consensus

3 /13
Active Models

Avg. confidence: 47%

What Is the Investment Case for AngioDynamics, Inc. (ANGO) in 2026?

What Is the Bull Case vs the Bear Case for AngioDynamics, Inc. (ANGO)?

Bull case versus bear case for AngioDynamics, Inc. (ANGO) at $15.78, derived from 3 active CirclFi valuation models on 2026-08-27.
Bull case Bear case — $0.80 target (-94.9%)
No active model projects meaningful upside for ANGO at $15.78. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $0.80 (-94.9%), suggesting that the market price embeds overly optimistic growth assumptions.
According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +58.8% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.

How Does ANGO Compare to Its Medical Instruments & Supplies Peers?

OSUR OraSure Technologies
6.8
AVTR Avantor, Inc.
6.5
BLFS BioLife Solutions, I
6.9
KRMD KORU Medical Systems
6.5
NXGL NEXGEL, Inc.
7.0
BAX Baxter International
6.3
BNGO Bionano Genomics, In
5.8
ALC Alcon Inc.
2.7

Valuation data pages: OSUR · AVTR · BLFS · KRMD · NXGL · BAX · BNGO · ALC · RGEN · ISRG · RMD

See full Medical Instruments & Supplies rankings →

Which Other Stocks Score Like ANGO on Quality?

Closest companies to ANGO’s Quality of Company score of 6.7/10, across all industries.

Why Do CirclFi’s 3 Models Disagree on ANGO?

Spread

1154%

Fair Value Range

$0.80 – $10.09

A 1154% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

FTNN

$10.09 (-36.1%)

Most Bearish

Bayesian DCF

$0.80 (-94.9%)

What Are the Biggest Risks of Buying ANGO Stock?

Model Disagreement

1154% spread signals high variance in projections.

Bearish Consensus

3/3 models suggest overvaluation.

Macro/Sector Risk

Medical Instruments & Supplies headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ANGO Data Page →

So Is AngioDynamics, Inc. (ANGO) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on AngioDynamics, Inc. at $15.78. 3/3 models flag overvaluation, median fair value sits at $1.11 (-93.0%), and the risk-reward profile appears unfavorable. Quality at 6.7/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. AngioDynamics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About ANGO Stock?

Should I buy ANGO stock right now?

Based on CirclFi's multi-model analysis, 0 of 3 models see upside for ANGO at $15.78. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in AngioDynamics, Inc.?

Key risks include: limited model coverage (3/13 active), reducing analytical confidence; wide model disagreement (1154% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Instruments & Supplies companies. Always diversify and consult a financial advisor.

How does ANGO compare to its competitors?

Among Medical Instruments & Supplies peers, ANGO holds a Quality Score of 6.7/10. Comparable companies include OSUR (QOC 6.8), AVTR (QOC 6.5), BLFS (QOC 6.9). The relative ranking helps investors identify whether ANGO offers better fundamental quality than alternatives in the same sector.

Is ANGO a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ANGO's Quality Score of 6.7/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy ANGO at?

CirclFi does not provide target buy prices or price alerts. However, our 3 active models produce fair value estimates ranging from $0.80 to $10.09. At $15.78, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ANGO.

View ANGO Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →